4 completed, 2 unknown, 1 withdrawn. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Unknown 2, Withdrawn 1 |
Follow Cryptococcosis: new trials by email Literature Review of Cryptococcosis trials Research Report on Cryptococcosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amphotericin B for Non-HIV Cryptococcal Meningitis Patients Amphotericin B 0.5 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks., Amphotericin B 0.7 mg/kg/day i.v. combined with flucytosine four times per day orally for the first 4 weeks. - Cryptococcal Meningitis, Antifungal Agents | Phase 4 | Unknown | Huashan Hospital | 250 | 2023-08-13 | 2023-12-21 |
| Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Liposomal amphotericin B - Cryptococcal Meningitis | Phase 4 | Unknown | Hui Bu | 40 | 2016-01-01 | 2016-02-22 |
| Operational Research for Cryptococcal Antigen Screening Fluconazole - Cryptococcal Meningitis, Cryptococcus Neoformans | Phase 4 | Completed | University of Minnesota | 3049 | 2012-07-01 | 2020-06-04 |
| Cryptococcal Optimal ART Timing Trial efavirenz, nucleoside - Cryptococcal Meningitis, HIV Infections | Phase 4 | Completed | University of Minnesota | 177 | 2010-11-01 | 2020-06-09 |
| Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis Early antiretroviral therapy - Cryptococcal Meningitis, HIV Infections | Phase 4 | Completed | Botswana-UPenn Partnership | 28 | 2009-09-01 | 2012-02-07 |
| Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex ABLC - Invasive Cryptococcosis | Phase 4 | Withdrawn | Medstar Health Research Institute | 2007-01-01 | 2021-02-17 | |
| A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Voriconazole - Candidiasis, Cryptococcosis | Phase 4 | Completed | Pfizer | 7 | 2003-04-01 | 2011-05-16 |
Meningitis, Cryptococcal (5) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Aspergillosis (1) · Candidiasis (1)
Bacterial Infections and Mycoses (7) · Infections (7) · Mycoses (7) · Central Nervous System Diseases (5) · Central Nervous System Fungal Infections (5) · Central Nervous System Infections (5) · Meningitis (5) · Meningitis, Fungal (5) · Nervous System Diseases (5) · Neuroinflammatory Diseases (5) · Blood-Borne Infections (3) · Communicable Diseases (3) · Genital Diseases (3) · Immune System Diseases (3)
Amphotericin B (1) · Fluconazole (1) · Lamivudine (1) · Nucleosides (1) · Stavudine (1) · Voriconazole (1) · Zidovudine (1) · efavirenz (1) · liposomal amphotericin B (1)
University of Minnesota (2) · Botswana-UPenn Partnership (1) · Huashan Hospital (1) · Hui Bu (1) · Medstar Health Research Institute (1) · Pfizer (1)
Uganda (2) · Botswana (1) · China (1) · South Africa (1) · Taiwan (1) · United States (1)
David B Meya, MMed (1) · David R Boulware, MD, MPH (1) · Gregory P Bisson, MD,MSCE (1) · Hui Bu, MD (1) · Pablo Tebas, MD (1) · Radha Rajasingham, MD (1) · Shmuel Shoham, MD (1)
PMID 23362285, PMID 24963568, PMID 30325463, PMID 30399034, PMID 31319498, PMID 31504335, PMID 32843994, PMID 39972326
U01AI089244 (1), U01GH000517 (1)